News

Stay up-to-date on our featured company developments as they achieve critical milestones. We will keep you informed as they announce clinical trial data, drug manufacturing updates, licensing agreements, presentations, and key additions to management.

Subscribe to Excellence

Welcome aboard! Your submission has been received and you are now a member of the MedicalGold.ca community.

Oops! Something went wrong while submitting the form. Please check the format of your entry.

News

Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office

PharmAla Biotech Signs Sale Agreement with Numinus

BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT

Numinus Wellness Submits Clinical Trial Application

Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office

Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million

Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin Announces Oversubscribed Private Placement of U.S. $150 Million

Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications

PharmAla named an Intellectual Property Ontario Client

MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business Update

BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.

Numinus Wellness Inc. Closes $6 Million Bought Deal Public Offering

Cybin Reports Third Quarter Financial Results and Recent Business Highlights

FendX Completes Third Pilot Run to Manufacture REPELWRAP(TM) Film using Dunmore's Commercial Equipment

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development

Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program

PharmAla releases Profitable Q1 Interim Financial Statement and Business Update

PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada

PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

FendX Completes Second Pilot Run to Manufacture REPELWRAP(TM) Film Using Dunmore's Commercial Equipment

Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-infused Psilocin)

Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

MindMed Announces Business Update and Anticipated Milestones for 2024

Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs

Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan

atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)

FendX Technologies Announces Non-Brokered Private Placement with Strategic Investors

Cedar Clinical Research selected as clinical research site for Beckley Psytech's Phase 2b Study

MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

FendX Signs Collaborative Research Agreement with McMaster for Development of Catheter Coating Using Its Nanotechnology

Numinus Wellness Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Results

Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results

Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program

Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

FendX Announces Publication of Data on Antimicrobial Properties of a New Nanotechnology Film Formulation that Both Repels and Kills Bacteria

FendX Technologies to Present at the SHARE(TM) Series Monday Management Update on December 4, 2023

Numinus to Host Q4 2023 and Annual Results Conference Call on November 29, 2023

Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City

FendX Provides Corporate Update

Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting

PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules

Cybin Announces up to US$64 Million Offering of Units

World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment

PharmAla Partners with Clariti Strategic Advisors™

FendX to Conduct Second Pilot Run on Dunmore's Commercial Manufacturing Line for Further Development of REPELWRAP(TM) Film

PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa

Cybin to Participate at the 2023 Milken Institute Future of Health Summit

MindMed Reports Third Quarter 2023 Financial Results and Business Highlights

FendX Announces Issuance of a Patent in China to Protect REPELWRAP(TM) Film

Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline

Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023

Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

FendX Engages nanoComposix For Scale-Up Development of Its Spray Nanotechnology

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update

Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs

Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program

MindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics

Small Pharma Reports Fiscal Second Quarter 2024 Highlights

FendX to Present at the Hidden Gems Conference and Available for Investor Meetings

Small Pharma Obtains Final Order Approving Arrangement

Cybin Announces Results of Annual and Special Meeting of Shareholders

Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit

Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit

FendX Successfully Completes Pilot Run to Manufacture REPELWRAP™ Film using Dunmore’s Commercial Equipment

Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research

Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder

MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress

Disposition of Common Shares of Small Pharma Inc.

FendX Technologies Inc. to Present at the Emerging Growth Conference on October 4, 2023

Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder

Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial

Cybin to Participate in the Cantor Global Healthcare Conference